Diagnosis and Management of Acute Kidney Injury
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (15 January 2023) | Viewed by 7212
Special Issue Editors
Interests: kidney; transplantation; immunology; fibrosis; kidney injury
Special Issues, Collections and Topics in MDPI journals
2. Nantong-Leicester Joint Institute of Kidney Science, Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, China
Interests: apoptosis; phagocytosis; inflommation; innate immunity and repair
Special Issue Information
Dear Colleagues,
Acute kidney injury (AKI) is a worldwide burden in our health care system. It occurs in about 13.3 million people per year, 85% of whom live in developing countries. Unfortunately, AKI is thought to contribute to about 1.7 million deaths every year, and, no specific prediction and treatment method is available so far. In 2015, the International Society of Nephrology initiated the “0by25” slogan for AKI (zero preventable deaths by 2025). With the development of diagnostic technology, we can detect AKI as early as serval hours. In animal models, various gene and cell therapies demonstrate exciting results. However, there are still so many issues that need to be solved in basic and clinic. In this Special Issue, we focus on AKI diagnosis and management. We welcome high-quality original basic, clinical and translational research, reviews and case reports. The topics are included but are not limited to:
- Novel biomarkers of AKI;
- New non-invasive diagnosis technology of AKI;
- Systemic or new management of AKI in clinic.
- New findings on AKI mechanisms;
- Novel therapy on AKI in translational studies.
Dr. Cheng Yang
Prof. Dr. Bin Yang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.